Historical Press Releases

2014

Soligenix Appoints Richard Straube, MD, as Chief Medical Officer

Princeton, NJ – January 6, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious...

Soligenix to Present at the 2014 Biotech Showcase in San Francisco

Princeton, NJ – January 9, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious...

Soligenix Announces Positive One-Year High-Temperature Stability Results with ThermoVax™ Vaccine Heat Stabilization Technology

Princeton, NJ – January 15, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious...

Soligenix Receives $750,000 in Non-Dilutive Financing from New Jersey’s Technology Business Tax Certificate Transfer Program

Princeton, NJ – January 16, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious...

Soligenix to Present at the 16th Annual BIO CEO & Investor Conference in New York City

Princeton, NJ – February 5, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious...

Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis

Princeton, NJ – February 14, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious...

Soligenix to Present at 2014 World Vaccine Congress in Washington, DC

Princeton, NJ – March 11, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory...

Soligenix Reports Year-End 2013 Financial Results and Highlights Recent Accomplishments

Princeton, NJ – March 26, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious...

Soligenix Announces $200,000 NIDCR SBIR Grant Award Supporting Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer

Princeton, NJ –April 7, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory...

Soligenix Reports First Quarter 2014 Financial Results, and Highlights Recent Accomplishments

Princeton, NJ – May 12, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory...

Soligenix Announces Combination Vaccine for Ricin and Anthrax Achieves Simultaneous Protection

Princeton, NJ – July 9, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory...

Soligenix Receives Additional NIAID Funding to Advance Development of OrbeShield™ in GI ARS

Princeton, NJ – August 1, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious...

Soligenix Advances Development of a Heat Stable Rapidly Acting Anthrax Vaccine VeloThrax™

Princeton, NJ – August 7, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious...

Soligenix Reports Second Quarter 2014 Financial Results, and Highlights Recent Accomplishments

Princeton, NJ – August 11, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious...

Soligenix Announces Positive Survival Results with Heat Stable Ricin Toxin Vaccine

Princeton, NJ – September 2, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious...

Soligenix Expands Pipeline with Acquisition of Phase 3-Ready Oncology Clinical Program

Princeton, NJ – September 5, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the...

Soligenix to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City

Princeton, NJ – September 8, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the...

Soligenix Announces Issuance of US Patent for ThermoVax™ Technology

Princeton, NJ – September 9, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the...

Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma

Princeton, NJ – September 17, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in...

Soligenix Awarded NIAID Contract Valued up to $24.7 Million for the Development of Heat Stable RiVax™ Vaccine

Princeton, NJ – September 19, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in...

Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development

Princeton, NJ – September 23, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in...

Soligenix Reports Third Quarter 2014 Financial Results, Highlighted with the Acquisition of SGX301, Synthetic Hypericin, for the Treatment of Cutaneous T-Cell Lymphoma

Princeton, NJ – November 10, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the...

Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board

Princeton, NJ – November 17, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the...

Soligenix Appoints Oreola Donini, PhD, as Chief Scientific Officer

Princeton, NJ – December 10, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the...

Soligenix Receives $617,000 in Non-Dilutive Financing from New Jersey’s Technology Business Tax Certificate Transfer Program

Princeton, NJ – December 11, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the...

Show per page